Polymer-directed crystallization of atorvastatin

Journal of Pharmaceutical Sciences

Volumn 101, Issue 8, 2012, Pages 2941-2951

  Choi, Hyemin ^a   Lee, Hyeseung ^a   Lee, Min Kyung ^a   Lee, Jonghwi ^a  

^a Chung Ang University   (South Korea)

Author keywords

Composite particles; Crystal engineering; Crystallization; Drying; Mesocrystals; Particle size; Polymer directed crystallization; Polymers

Indexed keywords

ATORVASTATIN; CHITOSAN; MACROGOL; POLYACRYLIC ACID; POLYETHYLENEIMINE; POLYMER;

ARTICLE; CRYSTAL; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DEGRADATION; DRUG STRUCTURE; MELTING POINT; MOLECULAR INTERACTION; PARTICLE SIZE; PHARMACEUTICAL ENGINEERING; SCANNING ELECTRON MICROSCOPY; STRUCTURE ANALYSIS; THREE DIMENSIONAL IMAGING; X RAY POWDER DIFFRACTION;

EID: 84862842920     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23206     Document Type: Article

References (34)

1. Huangand LF, Tong WQ. 2004. Impact of solid state properties on developability assessment of drug candidates. Adv Drug Deliv Rev 56:321-334.
2. Grzesiakand AL, Matzger AJ. 2007. New form discovery for the analgesics flurbiprofen and sulindac facilitated by polymer-induced heteronucleation. J Pharm Sci 96:2978-2986.
3. Grzesiak AL, Lang M, Kim K, Matzger AJ. 2003. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. J Pharm Sci 92:2260-2271.
4. Morissette SL, Almarsson O, Peterson ML, Remenar JF, Read MJ, Lemmo AV, Ellis S, Cima MJ, Gardner CR. 2004. High-throughput crystallization: Polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv Drug Deliv Rev 56:275-300.
5. Lee J, Lee S, Choi J, Yoo J, Ahn C. 2005. Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion. Eur J Pharm Sci 24:441-449.
6. Lee J. 2003. Drug nano- and microparticles processed into solid dosage forms: Physical properties. J Pharm Sci 92:2057-2068.
7. Rodriguez-Spong B, Price CP, Jayasankar A, Matzger AJ, Rodriguez-Hornedo N. 2004. General principles of pharmaceutical solid polymorphism: A supramolecular perspective. Adv Drug Deliv Rev 56:241-274.
8. Wohlrab S, Colfen H, Antonietti Crystalline M. 2005. Porous microspheres made from amino acids by using polymer-induced liquid precursor phases. Angew Chem Int Ed Engl 44:4087-4091.
9. Lang M, Grzesiak AL, Matzger AJ. 2002. The use of polymer heteronuclei for crystalline polymorph selection. J Am Chem Soc 124:14834-14835.
10. Grzesiak AL, Uribe FJ, Ockwig NW, Yaghi OM, Matzger AJ. 2006. Polymer-induced heteronucleation for the discovery of new extended solids. Angew Chem Int Ed Engl 45:2553.
11. Lopez-Mejias V, Kampf JW, Matzger AJ. 2009. Polymer-induced heteronucleation of tolfenamic acid: Structural investigation of a pentamorph. J Am Chem Soc 131:4554-4555.
12. Songand RQ, Colfen H. 2010. Mesocrystals-ordered nanoparticle superstructures. Adv Mater 22:1301-1330.
13. Colfen H. 2006. Bio-inspired mineralization using hydrophilic polymers. Topics Curr Chem 271:1-78.
14. Gower LA, Tirrell DA. 1998. Calcium carbonate films and helices grown in solutions of poly(aspartate). J Crystal Growth 191:153-160.
15. Antonietti M, Breulmann M, Goltner CG, Colfen H, Wong KKW, Walsh D, Mann S. 1998. Inorganic/organic mesostructures with complex architectures: Precipitation of calcium phosphate in the presence of double-hydrophilic block copolymers. Chem A Eur J 4:2493-2500.
16. Lee M, Choi H, Kim W, Hong J, Lee J. 2009. Influence of water soluble polymers on crystallization of 5-guanosine monophosphate. Polymer (Korea) 33:124-130.
17. Lee T, Zhang CW. 2008. Dissolution enhancement by bio-inspired mesocrystals: the study of racemic (R, S)-(±)-sodium ibuprofen dihydrate. Pharm Res 25:1563-1571.
18. Saeedi M, Dallalpoor-Mohammadi N, Farid D. 2003. Prevention of crystal growth in acetaminophen suspensions by the use of polyvinyl pyrrolidone and bovine serum albumin. DARU J Pharm Sci 11:106-114.
19. Raghavan SL, Trividic A, Davis AF, Hadgraft J. 2001. Crystallization of hydrocortisone acetate: Influence of polymers. Int J Pharm 212:213-221.
20. Lennernas H. 2003. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141-1160.
21. Kim MS, Jin SJ, Kim JS, Park HJ, Song HS, Neubert RHH, Hwang S. 2008. Preparation J characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm 69:454-465.
22. Kim JS, Kim MS, Park HJ, Jin SJ, Lee S, Hwang SJ. 2008. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. Int J Pharm 359:211-219.
23. Mohammadi A, Rezanour N, Ansari M, Dogaheh F, Ghorbani Bidkorbeh, Hashem M, Walker RB. 2007. A stability-indicating high performance liquid chromatographic (HPLC) assay for the simultaneous determination of atorvastatin and amlodipine in commercial tablets. J Chromatogr B 846:215-221.
24. Hoei Y, Yamaura K, Matsuzawa S. 1992. A lattice treatment of crystalline solvent-amorphous polymer mixtures on melting point depression. J Phys Chem 96:10584-10586.
25. Marsac PJ, Shamblin SL, Taylor LS. 2006. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res 23:2417-2426.
26. Gupta P, Kakumanu VK, Bansal AK. 2004. Stability and solubility of celecoxib-PVP amorphous dispersions: A molecular perspective. Pharm Res 21:1762-1769.
27. Gupta P, Thilagavathi R, Chakraborti AK, Bansal AK. 2005. Role of molecular interaction in stability of celecoxib-PVP amorphous systems. Mol Pharm 2:384-391.
28. Li H, Xin HL, Muller DA, Estroff LA. 2009. Visualizing the 3D internal structure of calcite single crystals grown in agarose hydrogels. Science 326:1244.
29. Gebauer D, Volkel A, Colfen H. 2008. Stable prenucleation calcium carbonate clusters. Science 322:1819.
30. Bergese P, Colombo I, Gervasoni D, Depero L. 2004. Melting of nanostructured drugs embedded into a polymeric matrix. J Phys Chem B 108:15488-15493.
31. Zhang J, Bunker M, Chen X, Parker A, Patel N, Roberts C. 2009. Nanoscale thermal analysis of pharmaceutical solid dispersions. Int J Pharm 380:170-173.
32. Liu X, Yang P, Jiang Q. 2007. Size effect on melting temperature of nanostructured drugs. Mater Chem Phys 103:1-4.
33. Schmidt AG, Wartewig S, Picker KM. 2003. Potential of carrageenans to protect drugs from polymorphic transformation. Eur J Pharm Biopharm 56:101-110.
34. Ma X, Taw J, Chiang CM. 1996. Control of drug crystallization in transdermal matrix system. Int J Pharm 142:115-119.